// App-Quantinova.ai

: Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Researchers

Presenter

  • Heinz Gisslinger

Principal Investigators

  • Bettina Gisslinger

  • Martin Schalling

  • Kurt Krejcy

  • Rudolf S. Widmann

  • Robert Kralovics

  • Maria-Theresa Krauth

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

  • AOP Orphan Pharmaceuticals AG, Vienna, Austria

  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myeloid neoplasms

  • Portal Hypertension

  • Myelofibrosis

  • Hypertension

  • Venous thrombosis

  • Anemia

Biomarkers

  • Calreticulin

  • Lymphocyte count

  • White Blood Cell

  • Interferon

Drug/Treatment

  • Interferon alpha

  • Pegylated interferon alfa-2b

  • Peginterferon alfa-2a

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved